Expression of oestrogen receptor-β in apocrine carcinomas of the breast

Histopathology

Volumn 50, Issue 4, 2007, Pages 425-433

  Honma, N ^a,b   Takubo, K ^a   Akiyama, F ^b   Kasumi, F ^c   Sawabe, M ^d   Arai, T ^d   Hosoi, T ^d   Yoshimura, N ^e   Harada, N ^e   Younes, M ^f   Sakamoto, G ^b  

^a TOKYO METROPOLITAN INSTITUTE OF GERONTOLOGY   (Japan)

^b CANCER INSTITUTE   (Japan)

^c CANCER INSTITUTE HOSPITAL   (Japan)

^d Tokyo Metropolitan Institute of Gerontology   (Japan)

^e FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Apocrine carcinoma; Breast; Oestrogen receptor

Indexed keywords

ESTROGEN RECEPTOR BETA; MESSENGER RNA;

ADULT; AGED; APOCRINE CARCINOMA; ARTICLE; BREAST CARCINOMA; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MIDDLE AGED; RECEPTOR, ERBB-2; RECEPTORS, ANDROGEN; RECEPTORS, PROGESTERONE; RNA, MESSENGER;

EID: 33847259215     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2007.02636.x     Document Type: Article

References (47)

1. Azzopardi JG. Problems in breast pathology. Major problems in pathology, Vol. 11. London: W.B. Saunders 1979; 341-344.
2. Frable WJ, Kay S. Carcinoma of the breast. Histologic and clinical features of apocrine tumors. Cancer 1968; 21; 756-763.
3. Mossler JA, Barton TK, Brinkhous AD, McCarty KS, Moylan JA, McCarty KS. Apocrine differentiation in human mammary carcinoma. Cancer 1980; 46; 2463-2471.
4. Abati AD, Kimmel M, Rosen PP. Apocrine mammary carcinoma. A clinicopathologic study of 72 cases. Am. J. Clin. Pathol. 1990; 94; 371-377.
5. Honma N, Sakamoto G, Akiyama F et al. Breast carcinoma in women over the age of 85: distinct histological pattern and androgen, oestrogen, and progesterone receptor status. Histopathology 2003; 42; 120-127.
6. Japaze H, Emina J, Diaz C et al. 'Pure' invasive apocrine carcinoma of the breast: a new clinicopathological entity? Breast 2005; 14; 3-10.
7. Tavassoli FA, Purcell CA, Bratthauer GL, Man YG. Androgen receptor expression along with loss of bcl-2, ER, and PR expression in benign and malignant apocrine lesions of the breast: implications for therapy. Breast J. 1996; 2; 261-269.
8. Leal C, Henrique R, Monteiro P et al. Apocrine ductal carcinoma in situ of the breast: histologic classification and expression of biologic markers. Hum. Pathol. 2001; 32; 487-493.
9. Gatalica Z. Immunohistochemical analysis of apocrine breast lesions. Consistent over-expression of androgen receptor accompanied by the loss of estrogen and progesterone receptors in apocrine metaplasia and apocrine carcinoma in situ. Pathol. Res. Pract. 1997; 193; 753-758.
10. Honma N, Takubo K, Akiyama F et al. Expression of GCDFP-15 and AR decrease in larger or node-positive apocrine carcinomas of the breast. Histopathology 2005; 47; 195-201.
11. Birrell SN, Roder DM, Horsfall DJ, Bentel JM, Tilley WD. Medroxyprogesterone acetate therapy in advanced breast cancer: the predictive value of androgen receptor expression. J. Clin. Oncol. 1995; 13; 1572-1577.
12. Honma N, Takubo K, Sawabe M et al. Estrogen-metabolizing enzymes in breast cancers from women over the age of 80 years. J. Clin. Endocrinol. Metab. 2006; 91; 607-613.
13. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JÅ. Cloning of a novel receptor expressed in rat prostate and ovary. Proc. Natl Acad. Sci. USA 1996; 93; 5925-5930.
14. Weihua Z, Andersson S, Cheng G, Simpson ER, Warner M, Gustafsson JÅ. Update on estrogen signaling. FEBS Lett. 2003; 546; 17-24.
15. Moore JT, McKee DD, Slentz-Kesler K et al. Cloning and characterization of human estrogen receptor β isoforms. Biochem. Biophys. Res. Commun. 1998; 247; 75-78.
16. Speirs V, Parkes AT, Kerin MJ et al. Coexpression of estrogen receptor α and β: poor prognostic factors in human breast cancer? Cancer Res. 1999; 59; 525-528.
17. Järvinen TAH, Pelto-Huikko M, Holli K, Isola J. Estrogen receptor b is coexpressed with ERα and PR and associated with nodal status, grade, and proliferation rate in breast cancer. Am. J. Pathol. 2000; 156; 29-35.
18. Mann S, Laucirica R, Carlson N et al. Estrogen receptor beta expression in invasive breast cancer. Hum. Pathol. 2001; 32; 113-118.
19. Fuqua SAW, Schiff R, Parra I et al. Estrogen receptor β protein in human breast cancer: correlation with clinical tumor parameters. Cancer Res. 2003; 63; 2434-2439.
20. Omoto Y, Inoue S, Ogawa S et al. Clinical value of the wild-type estrogen receptor beta expression in breast cancer. Cancer Lett. 2001; 163; 207-212.
21. Saji S, Omoto Y, Shimizu C et al. Expression of estrogen receptor (ER) βcx protein in ERα-positive breast cancer: specific correlation with progesterone receptor. Cancer Res. 2002; 62; 4849-4853.
22. Leygue E, Dotzlaw H, Watson PH, Murphy LC. Expression of estrogen receptor β1, β2, and β5 messenger RNAs in human breast tissue. Cancer Res. 1999; 59; 1175-1179.
23. Speirs V, Carder PJ, Lane S, Dodwell D, Lansdown MRJ, Hanby AM. Oestrogen receptor β: what it means for patients with breast cancer. Lancet Oncol. 2004; 5; 174-181.
24. Savinov AY, Remacle AG, Golubkov VS et al. Matrix metalloproteinase 26 proteolysis of the NH2-terminal domain of the estrogen receptor β correlates with the survival of breast cancer patients. Cancer Res. 2006; 66; 2716-2724.
25. Tavassoli FA, Devilee P eds. World Health Organization classification of tumours. Pathology and genetics of tumours of the breast and female genital organs. Lyon: IARC Press 2003.
26. Tavassoli FA, Norris HJ. Intraductal apocrine carcinoma: a clinicopathologic study of 37 cases. Mod. Pathol. 1994; 7; 813-818.
27. Mazoujian G, Pinkus GS, Davis S, Haagensen DE. Immunohistochemistry of a gross cystic disease fluid protein (GCDFP-15) of the breast. A marker of apocrine epithelium and breast carcinomas with apocrine features. Am. J. Pathol. 1983; 110; 105-112.
28. Castagna M, Nuti M, Squartini F. Mammary cancer antigen recognized by monoclonal antibody B72.3 in apocrine metaplasia of the human breast. Cancer Res. 1987; 47; 902-906.
29. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19; 403-410.
30. Galea MH, Blamey RW, Elston CE, Ellis IO. The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res. Treat. 1992; 22; 207-219.
31. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J. Clin. Oncol. 2003; 21; 3357-3365.
32. Nakopoulou L, Lazaris AC, Panayotopoulou EG et al. The favourable prognostic value of oestrogen receptor β immunohistochemical expression in breast cancer. J. Clin. Pathol. 2004; 57; 523-528.
33. Kuenen-Boumeester V, Van der Kwast TH, van Putten WL, Claassen C, van Ooijen B, Henzen-Logmans SC. Immunohistochemical determination of androgen receptors in relation to oestrogen and progesterone receptors in female breast cancer. Int. J. Cancer 1992; 52; 581-584.
34. Chirgwin JM, Przybyla AE, MacDonald RJ, Rutter WJ. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry 1979; 18; 5294-5299.
35. Utsumi T, Yoshimura N, Takeuchi S et al. Steroid sulfatase expression is an independent predictor of recurrence in human breast cancer. Cancer Res. 1999; 59; 377-381.
36. Skliris GP, Parkes AT, Limer JL, Burdall SE, Carder PJ, Speirs V. Evaluation of seven oestrogen receptor β antibodies for immunohistochemistry, western blotting, and flow cytometry in human breast tissue. J. Pathol. 2002; 197; 155-162.
37. Skliris GP, Carder PJ, Lansdown MRJ, Speirs V. Immunohistochemical detection of ER-β in breast cancer: towards more detailed receptor profiling? Br. J. Cancer 2001; 84; 1095-1098.
38. Roger P, Sahla ME, Mäkelä S, Gustafsson JÅ, Baldet P, Rochefort H. Decreased expression of estrogen receptor β protein in proliferative preinvasive mammary tumors. Cancer Res. 2001; 61; 2537-2541.
39. Paech K, Webb P, Kuiper GG et al. Differential ligand activation of estrogen receptors ERα and ERβ at AP1 sites. Science 1997; 277; 1508-1510.
40. Omoto Y, Eguchi H, Yamamoto-Yamaguchi Y, Hayashi S. Estrogen receptor (ER) β1 and ERβcx/β2 inhibit ERα function differently in breast cancer cell line MCF7. Oncogene 2003; 22; 5011-5020.
41. Cappelletti V, Veneroni S, Coradini D et al. Re: Tamoxifen may be an effective treatment for BRCA1-related breast cancer irrespective of estrogen receptor status. J. Natl Cancer Inst. 2003; 95; 629-630.
42. Haagensen DE, Stewart P, Dilley WG, Wells SA. Secretion of breast gross cystic disease fluid proteins by T47D breast cancer cells in culture - modulation by steroid hormones. Breast Cancer Res. Treat. 1992; 23; 77-86.
43. Yang SH, Liu R, Perez EJ et al. Mitochondrial localization of estrogen receptor β. Proc. Natl Acad. Sci. USA 2004; 101; 4130-4135.
44. Chen JQ, Delannoy M, Cooke C, Yager JD. Mitochondrial localization of ERα and ERβ in human MCF7 cells. Am. J. Physiol. Endocrinol. Metab. 2004; 286; E1011-E1022.
45. Milner TA, Ayoola K, Drake CT et al. Ultrastructural localization of estrogen receptor β immunoreactivity in the rat hippocampal formation. J. Comp. Neurol. 2005; 491; 81-95.
46. Tavassoli FA. Pathology of the breast. New York: McGraw-Hill 1992; 508-511.
47. Isola JJ. Immunohistochemical demonstration of androgen receptor in breast cancer and its relationship to other prognostic factors. J. Pathol. 1993; 170; 31-35.